Presentation is loading. Please wait.

Presentation is loading. Please wait.

Akshaya Bio Inc.…..…………..focus is on vaccines 11 Chimigen® Technology-Based Molecular Vaccines Akshaya Bio Inc. InnovationScan November, 2013.

Similar presentations


Presentation on theme: "Akshaya Bio Inc.…..…………..focus is on vaccines 11 Chimigen® Technology-Based Molecular Vaccines Akshaya Bio Inc. InnovationScan November, 2013."— Presentation transcript:

1 Akshaya Bio Inc.…..…………..focus is on vaccines 11 Chimigen® Technology-Based Molecular Vaccines Akshaya Bio Inc. InnovationScan November, 2013

2 Akshaya Bio Inc.…..…………..focus is on vaccines 2 Akshaya Bio Inc. Outline The Company  Management  Research Team  Collaborators Chimigen® Platform Technology  Unique Features  Product Pipeline  Status Highlights Contacts

3 Akshaya Bio Inc.…..…………..focus is on vaccines 3 Akshaya Bio Inc.- Current Based in Edmonton, Alberta  8223 Roper Road  Currently a team of Nine, Eight Researchers (7 Ph.Ds, 1 B.Sc. 1 MBA) Founded in 2010  Dendritic cell receptor-targeted vaccines  Proprietary technology 16 issued patents 32 patents pending worldwide  Acquired Chimigen® Technology from Paladin Labs Inc. and ViRexx Medical Corp., (TSX, AMEX) External Partners in Research and Development  NRC-IRAP, CHTD, AITF, Gates Foundation Unique technology platform  Improved antigen presentation Rich Product Pipeline  HBV, HCV, HIV, Cancer, Malaria, Biodefense, Influenza,

4 Akshaya Bio Inc.…..…………..focus is on vaccines Management Team Satish Chandran, Ph.D Chief Executive Officer Rajan George, M.Sc, Ph.D President and Chief Scientific Officer Bruce Hirsche, QC General & Intellectual Property Counsel Rohit George, BA, MBA Business Operations 4

5 Akshaya Bio Inc.…..…………..focus is on vaccines Research Team Allan Ma, Ph.D Senior Scientist, Virologist Dakun Wang, Ph.D Senior Scientist, Immunologist Yun Xia, Ph.D Cell Biologist/Immunologist Morris Kostiuk, Ph.D Biochemist/Molecular Biologist Gina Thede, Ph.D Biochemist/Molecular Biologist Hue Anh Luu, B.Sc Technologist 5

6 Akshaya Bio Inc.…..…………..focus is on vaccines Collaborators 6 NRC/IRAP –Eric Swanson, Ph.D Nuron Biotech –HBV Vaccine License –HCV Vaccine License Option University of Alberta- HBV & HCV Clinical Research –Klaus Gutfreund, M.D, Assoc. Professor, Medicine, U of A –Mang Ma, M.D, Assoc. Professor, Medicine, U of A VIDO/InterVac-Immunology in Animals –Qiang Li, Ph.D NRC-NINT-Nanoparticles –Nils Peterson, Ph.D CHTD/Gates Foundation DRDC Suffield –Les Nagata, Ph.D (Head Biotechnology Section) NIH –HBV & HCV

7 Akshaya Bio Inc.…..…………..focus is on vaccines Chimigen® Platform Technology 7 Novel Approach to an Established Concept Dendritic Cell Receptor-Targeted Vaccines

8 Akshaya Bio Inc.…..…………..focus is on vaccines Chimigen®- A Platform Technology Chimigen® Recombinant Molecule 8 Strong Intellectual Property Position 16 Issued Patents, 32 Patent Applications Pending worldwide

9 Akshaya Bio Inc.…..…………..focus is on vaccines Chimigen®- A Platform Technology Characteristics of both Antigen (Ag) and Antibody (Ab) Xenotypic (foreign) Ab fragment makes whole molecule “foreign” & thus more immunogenic Adaptable platform –Adaptable to disease-specific multiple molecular antigenic epitopes –HBV, HCV, HIV, Biodefense Applications (Alphaviruses), Pandemic Preparedness (H5N1, H1N1), Malaria, Cancer etc. Designed to generate broad immune responses –Cellular (Class I)- critical to clear virus infected & cancer cells –Humoral (Class II)- Antibodies Potential use for both Prophylactic & Therapeutic Vaccines 9

10 Akshaya Bio Inc.…..…………..focus is on vaccines Chimigen®- A Platform Technology Effective at low doses (µg) –Targets multiple cell types relevant to immune activation –Targets multiple specific receptors on Antigen Presenting Cells Dendritic Cells (Fcy, Lectin Receptors) Minimal safety concerns –Utilizes classical antigen presentation pathway –No added adjuvant Eliminates many adverse events Eliminates T cell sequestration, dysfunction & deletion (Nat. Med. 2013, Lu. et al) Ease of production and scalability –Utilizes insect cell-based production Increased antigenicity through production of the chimeric molecule in Insect Cells Imparts non-mammalian glycosolation; Highly immunogenic Established purification systems Binding and uptake through Fc and Lectin receptors 10

11 Akshaya Bio Inc.…..…………..focus is on vaccines Product Pipeline & Status HBV Therapeutic/Prophylactic Vaccine Preclinical completed (Licensed to Nuron, co-development) HCV Therapeutic/Prophylactic Vaccine Preclinical (Nuron co-development, option to license) HIV Prophylactic/Therapeutic Vaccine Discovery (CHTD-NRC-IRAP) Cancer Vaccine Discovery Malaria Late discovery stage (Gates Foundation); ready for animal studies Biodefense and Pandemic Applications Alphavirus (WEEV) Vaccine, Discovery/Preclinical Influenza H5 & H1 Pre-clinical 11

12 Akshaya Bio Inc.…..…………..focus is on vaccines Akshaya’s Competitive Advantages Meets major unmet needs  No vaccine/therapy available Efficacy, it works  Proof of Concept established  HBV Chronic Carriers  Breaking Tolerance No Adjuvant  Eliminates majority of the adverse reactions  The Scare Factor  Eliminates production of “dysfunctional CTLs” Re-educating the immune system  Uses Dendritic Cell Receptor  Natural endogenous process for uptake and presentation of antigens & induction of broad immune responses 12

13 Akshaya Bio Inc.…..…………..focus is on vaccines Chimigen® Vaccine Highlights Highlights Versatile, Adaptable Platform Dendritic Cell Receptor-Targeted Vaccines Generates broad immune responses –Cellular (Class I)- critical to clear virus infected & cancer cells –Humoral (Class II)- Abs- Helps CTLs Proof of principle established with Chimigen® HBV Therapeutic Vaccine Potential use for both Prophylactic & Therapeutic Vaccines Strong Intellectual Property Position 13

14 Akshaya Bio Inc.…..…………..focus is on vaccines Contacts 14 Satish Chandran, Ph.D Chief Executive Officer 8223 Roper Road Edmonton Alberta, T6E 6S4 Canada Mobile: Web: Rajan George, M.Sc, Ph.D President & Chief Scientific Officer 8223 Roper Road Edmonton Alberta, T6E 6S4 Canada Telephone: Mobile: Web:

15 Akshaya Bio Inc.…..…………..focus is on vaccines Akshaya Bio Inc. Thank You……. 15


Download ppt "Akshaya Bio Inc.…..…………..focus is on vaccines 11 Chimigen® Technology-Based Molecular Vaccines Akshaya Bio Inc. InnovationScan November, 2013."

Similar presentations


Ads by Google